Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518173) titled 'A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Condition:
HER2-positive Breast Cancer
Intervention:
Drug: BL-M07D1
Drug: Pertuzumab
Drug: Trastuzumab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: April 2026
Target Sample S...